Hipertension y Riesgo Vascular最新文献_第2页

Prevalence, trends, and associated factors of isolated systolic, diastolic, and systolic–diastolic hypertension in Peru: A nine-year analysis of the Demographic and Family Health Survey 秘鲁孤立性收缩期、舒张期和收缩期-舒张期高血压的患病率、趋势和相关因素：人口与家庭健康调查九年分析》。

IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Hipertension y Riesgo Vascular

Pub Date : 2025-01-01 DOI: 10.1016/j.hipert.2024.10.001

V.J. Vera-Ponce , F.E. Zuzunaga-Montoya , L.E.M. Vásquez-Romero , J.A. Loayza-Castro , C.I. Gutierrez De Carrillo , E. Vigil-Ventura

Introduction

While HTN is widely seen as a primary threat to cardiovascular conditions worldwide, it is essential to recognize that not all HTN is identical.

Objective

To determine the prevalence, trend, and factors associated with each type of HTN: isolated systolic (ISH), isolated diastolic (IDH), and systolic–diastolic (SDH).

Methods

A secondary analysis of data from the Demographic and Family Health Survey from 2014 to 2022 was conducted. For the analysis of associated factors, a Poisson regression model with robust variance was implemented to calculate adjusted prevalence ratios (aPR) along with their 95% confidence intervals.

Results

The prevalence was 7.02%, 1.55%, and 3.28% for ISH, IDH, and SDH, respectively. ISH showed a decline in 2022, unlike the other two types, which seem to be on the rise. A statistically significant association was found in men and an increased risk with age for ISH and SDH, unlike IDH, where age acts as a protective factor. Additional factors identified include smoking and excessive alcohol consumption, while a high intake of fruits/vegetables offers a protective effect. Obesity and diabetes were associated with a higher risk, and significant variations by region and altitude, as well as among ethnic groups, were observed.

Conclusions

Significant differences in the prevalence of HTN subtypes have been found, underscoring the heterogeneity of this chronic condition, both in related factors and in trends over the years.

导言：虽然高血压被广泛视为全球心血管疾病的主要威胁，但必须认识到并非所有高血压都相同：确定每种类型高血压的患病率、趋势和相关因素：孤立收缩压（ISH）、孤立舒张压（IDH）和收缩-舒张压（SDH）：对 2014 年至 2022 年人口与家庭健康调查的数据进行了二次分析。为了分析相关因素，采用了具有稳健方差的泊松回归模型来计算调整患病率（aPR）及其 95% 的置信区间：ISH、IDH和SDH的患病率分别为7.02%、1.55%和3.28%。ISH在2022年呈下降趋势，而其他两种类型似乎呈上升趋势。在统计学上发现，ISH 和 SDH 与男性有明显关联，随着年龄的增长，患病风险也会增加，而 IDH 则不同，年龄是一个保护因素。发现的其他因素包括吸烟和过度饮酒，而摄入大量水果/蔬菜则具有保护作用。肥胖和糖尿病与较高的风险有关，不同地区、不同海拔以及不同种族群体之间存在显著差异：结论：研究发现，高血压亚型的患病率存在显著差异，这凸显了这种慢性疾病在相关因素和多年趋势方面的异质性。

{"title":"Prevalence, trends, and associated factors of isolated systolic, diastolic, and systolic–diastolic hypertension in Peru: A nine-year analysis of the Demographic and Family Health Survey","authors":"V.J. Vera-Ponce , F.E. Zuzunaga-Montoya , L.E.M. Vásquez-Romero , J.A. Loayza-Castro , C.I. Gutierrez De Carrillo , E. Vigil-Ventura","doi":"10.1016/j.hipert.2024.10.001","DOIUrl":"10.1016/j.hipert.2024.10.001","url":null,"abstract":"<div><h3>Introduction</h3><div>While HTN is widely seen as a primary threat to cardiovascular conditions worldwide, it is essential to recognize that not all HTN is identical.</div></div><div><h3>Objective</h3><div>To determine the prevalence, trend, and factors associated with each type of HTN: isolated systolic (ISH), isolated diastolic (IDH), and systolic–diastolic (SDH).</div></div><div><h3>Methods</h3><div>A secondary analysis of data from the Demographic and Family Health Survey from 2014 to 2022 was conducted. For the analysis of associated factors, a Poisson regression model with robust variance was implemented to calculate adjusted prevalence ratios (aPR) along with their 95% confidence intervals.</div></div><div><h3>Results</h3><div>The prevalence was 7.02%, 1.55%, and 3.28% for ISH, IDH, and SDH, respectively. ISH showed a decline in 2022, unlike the other two types, which seem to be on the rise. A statistically significant association was found in men and an increased risk with age for ISH and SDH, unlike IDH, where age acts as a protective factor. Additional factors identified include smoking and excessive alcohol consumption, while a high intake of fruits/vegetables offers a protective effect. Obesity and diabetes were associated with a higher risk, and significant variations by region and altitude, as well as among ethnic groups, were observed.</div></div><div><h3>Conclusions</h3><div>Significant differences in the prevalence of HTN subtypes have been found, underscoring the heterogeneity of this chronic condition, both in related factors and in trends over the years.</div></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"42 1","pages":"Pages 18-28"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142649244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trastornos hipertensivos de novo en el posparto: consideraciones sobre su diagnóstico, factores de riesgo y posibles estrategias de intervención [产后新发高血压疾病：关于诊断、风险因素和潜在干预策略的考虑]。

IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Hipertension y Riesgo Vascular

Pub Date : 2025-01-01 DOI: 10.1016/j.hipert.2024.09.001

P.G. Irusta

Postpartum de novo arterial hypertension (PPDNAH) is defined as blood pressure ≥140/90 mmHg, without a history of hypertension during pregnancy or delivery. Its prevalence ranges from 0.3% to 27.5% of all pregnancies. Late-onset postpartum preeclampsia (LOPPP) and late-onset postpartum eclampsia (LOPPE) typically occur between 48 hours and 6 weeks postpartum, although recent studies demonstrate the possibility of developing these disorders up to 12 months postpartum.

While sharing risk factors with pregnancy-related disorders, they differ in some aspects such as primigravida status. Regarding prognosis, an increase in severe maternal morbidity has been observed compared to hypertensive disorders of pregnancy.

This group of pathologies is often underdiagnosed, even in high-risk patients, making early identification along with strict blood pressure monitoring essential.

产后新发动脉高血压（PPDNAH）的定义是血压≥140/90mmHg，且在怀孕或分娩期间没有高血压病史。其发病率占所有妊娠的 0.3% 至 27.5%。晚发性产后子痫前期（LOPPP）和晚发性产后子痫（LOPPE）通常发生在产后 48 小时至 6 周之间，但最近的研究表明，这些疾病有可能在产后 12 个月内发生。虽然与妊娠相关疾病具有相同的风险因素，但它们在某些方面（如初产妇身份）有所不同。在预后方面，与妊娠期高血压疾病相比，产妇的严重发病率有所上升。这类病症往往诊断不足，甚至在高危患者中也是如此，因此必须及早发现并进行严格的血压监测。

引用次数: 0

Metastatic pheochromocytoma: An unusual case and its multidisciplinary management 转移性嗜铬细胞瘤：一个不寻常的病例及其多学科治疗。

IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Hipertension y Riesgo Vascular

Pub Date : 2025-01-01 DOI: 10.1016/j.hipert.2024.09.002

J.M. Ruiz-Cánovas , E.A. Achote-Rea , T. Alonso-Gordoa , A. Martínez-Lorca , M. Araujo-Castro

We describe the case of an 80-year-old man with sporadic right pheochromocytoma who developed metastatic disease six years after initial diagnosis. Despite adequate blood pressure control and initial biochemical cure criteria after surgery, elevated chromogranin A levels were detected during routine screening, which anticipated elevated 24-h urine metanephrines. Subsequent imaging tests revealed metastatic lesions in the lungs, liver, prostate and lymph nodes. The patient underwent systemic treatment with [131I] MIBG, which resulted in a decrease in chromogranin A levels, achieving radiological and clinical stability. This case highlights the importance of long-term follow-up and biochemical monitoring for early detection of tumor recurrence in patients with pheochromocytoma, emphasizing the need for individualized treatment strategies and interdisciplinary care.

我们描述了一例患有散发性右侧嗜铬细胞瘤的 80 岁男性病例，他在初次确诊六年后出现了转移性疾病。尽管手术后血压得到了充分控制，并达到了最初的生化治愈标准，但在常规筛查中发现嗜铬粒蛋白 A 水平升高，这预示着 24 小时尿中的甲肾上腺素升高。随后的影像学检查发现肺部、肝脏、前列腺和淋巴结有转移病灶。患者接受了[131I] MIBG的全身治疗，结果嗜铬粒蛋白A水平有所下降，达到了放射学和临床稳定。本病例强调了长期随访和生化监测对于早期发现嗜铬细胞瘤患者肿瘤复发的重要性，强调了个体化治疗策略和跨学科护理的必要性。

引用次数: 0

The reference arm – The eternal doubt 参考臂-永恒的怀疑。

IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Hipertension y Riesgo Vascular

Pub Date : 2025-01-01 DOI: 10.1016/j.hipert.2024.12.003

N. Soldevila Bacardit, E. Vinyoles Bargalló

引用次数: 0

Position paper on the 2024 ESH clinical practice guidelines for the management of arterial hypertension in Spain 关于 2024 年西班牙动脉高血压管理 ESH 临床实践指南的立场文件。

IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Hipertension y Riesgo Vascular

Pub Date : 2025-01-01 DOI: 10.1016/j.hipert.2024.09.003

E. Rodilla , M. Benítez Camps , L. Castilla Guerra , M.I. Egocheaga Cabello , J. Gamarra Ortiz , M.Á. María Tablado , N. Muñoz Rivas , V. Pallarés-Carratalá , J. Polo García , J.A. García Donaire

The 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension (ESH Guidelines 2024) have recently been published, a brief document but with a very elaborate infographic that summarizes as much as possible the previous guidelines for the management of arterial hypertension (HTN), aimed at serving as a quick reference tool to make decisions in daily clinical practice. The main objective of this work is to analyze the recommendations and innovations of these guidelines from the perspective of their applicability and taking into account all the scientific societies in the specialty of Family and Community Medicine, Internal Medicine and the Spanish Society of Hypertension (SEHLELHA) in order to achieve more homogeneous and evidence-based care for HTN in Spain. The most important results include the maintenance of the thresholds to define HTN and the therapeutic objectives, as well as the recommendation to initiate pharmacological treatment based on both the blood pressure values and the cardiovascular risk estimated by SCORE2 and the presence of organic damage. New are the introduction of practical tables to estimate the fragility of hypertensive subjects based on their age and autonomy, as well as precise recommendations for monitoring HTN. In summary, the ESH 2024 Guidelines represent a useful, reasoned and concise instrument that can serve as a tool to improve the control of HTN in our environment.

欧洲高血压学会 2024 年动脉高血压管理临床实践指南（ESH 指南 2024）已于近期发布，这是一份简短的文件，但其信息图却非常精致，尽可能地总结了之前的动脉高血压（HTN）管理指南，旨在作为日常临床实践中决策的快速参考工具。这项工作的主要目的是从适用性的角度分析这些指南的建议和创新，同时考虑到家庭与社区医学、内科医学和西班牙高血压学会（SEHLELHA）等专业领域的所有科学协会，以便在西班牙实现更加统一和循证的高血压治疗。最重要的成果包括保留了界定高血压的阈值和治疗目标，以及根据血压值和 SCORE2 估算的心血管风险以及是否存在器质性损害来启动药物治疗的建议。新内容包括引入实用表格，根据高血压患者的年龄和自理能力估算其脆性，以及监测高血压的精确建议。总之，《ESH 2024 指南》是一份有用、合理且简明的文书，可作为改善我们环境中高血压控制的工具。

{"title":"Position paper on the 2024 ESH clinical practice guidelines for the management of arterial hypertension in Spain","authors":"E. Rodilla , M. Benítez Camps , L. Castilla Guerra , M.I. Egocheaga Cabello , J. Gamarra Ortiz , M.Á. María Tablado , N. Muñoz Rivas , V. Pallarés-Carratalá , J. Polo García , J.A. García Donaire","doi":"10.1016/j.hipert.2024.09.003","DOIUrl":"10.1016/j.hipert.2024.09.003","url":null,"abstract":"<div><div>The 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension (ESH Guidelines 2024) have recently been published, a brief document but with a very elaborate infographic that summarizes as much as possible the previous guidelines for the management of arterial hypertension (HTN), aimed at serving as a quick reference tool to make decisions in daily clinical practice. The main objective of this work is to analyze the recommendations and innovations of these guidelines from the perspective of their applicability and taking into account all the scientific societies in the specialty of Family and Community Medicine, Internal Medicine and the Spanish Society of Hypertension (SEHLELHA) in order to achieve more homogeneous and evidence-based care for HTN in Spain. The most important results include the maintenance of the thresholds to define HTN and the therapeutic objectives, as well as the recommendation to initiate pharmacological treatment based on both the blood pressure values and the cardiovascular risk estimated by SCORE2 and the presence of organic damage. New are the introduction of practical tables to estimate the fragility of hypertensive subjects based on their age and autonomy, as well as precise recommendations for monitoring HTN. In summary, the ESH 2024 Guidelines represent a useful, reasoned and concise instrument that can serve as a tool to improve the control of HTN in our environment.</div></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"42 1","pages":"Pages 52-58"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142682941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiovascular risk markers in apparently healthy young adults: Evaluation according to optimal or non-optimal office blood pressure. 在表面健康的年轻人心血管危险标志物：根据最佳或非最佳办公室血压评估。

IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Hipertension y Riesgo Vascular

Pub Date : 2024-12-30 DOI: 10.1016/j.hipert.2024.11.006

W Espeche, O A Pinilla, G Cerri, N Stavile, J Minetto, M R Salazar, I L Ennis

Background: Blood pressure (BP) is linearly related to the incidence of cardiovascular disease from values as low as 115/75mmHg, even at young ages. A particularly concerning issue is the decrease representation of optimal BP among children and youth. The mechanisms by which minimal elevations in BP increase cardiovascular risk are not defined. The limitations of office BP measurements could be a possible explanation since 24-h ambulatory measurements (ABPM) better detect the risk of future cardiovascular events. Therefore, we aimed to compare healthy normotensive undergraduate students with optimal vs. non-optimal BP: ABPM, the cardiometabolic risk profile, and echocardiographic characteristics.

Methods: Medical students from La Plata voluntarily completed a survey to collect personal and family data on cardiovascular risk factors. Subsequently, anthropometric, BP (office and ABPM), and echocardiography determinations were recorded. Cholesterol, triglycerides, and glucose were measured in fasting blood samples. Statistical analyses were performed blinded, using SPSS software.

Results: Data from 135 students were analyzed (76% female, age 22.5±3.5 years). Mean office BP was 114.5±10.4 and 73.7±7.5mmHg. Forty percent of students had non-optimal BP (61% females) showing significantly higher BP values in all ABPM periods and higher left ventricular mass index, cardiac wall thicknesses, fasting glucose, TyG index, TG/HDL-c ratio. Seven students met diagnostic criteria for nocturnal hypertension, six of whom were in the non-optimal BP group (11.1% vs 1.2%).

Conclusions: Therefore, our study shows that apparently healthy young individuals with non-optimal BP, even if not hypertensive, exhibit differences in several cardiovascular risk markers compared to those with optimal BP.

背景：血压（BP）与心血管疾病的发病率线性相关，低至115/75mmHg，即使在年轻时也是如此。一个特别值得关注的问题是儿童和青少年中最佳血压的代表性下降。最小血压升高增加心血管风险的机制尚未明确。办公室血压测量的局限性可能是一个可能的解释，因为24小时动态测量（ABPM）可以更好地检测未来心血管事件的风险。因此，我们的目的是比较健康的正常血压的大学生最佳与非最佳的血压：ABPM，心脏代谢风险概况和超声心动图特征。方法：拉普拉塔市医科学生自愿完成一项调查，收集个人和家庭的心血管危险因素资料。随后，记录人体测量、血压（办公室和ABPM）和超声心动图测定。在空腹血液样本中测量胆固醇、甘油三酯和葡萄糖。采用SPSS软件进行盲法统计分析。结果：分析了135名学生的资料（76%为女性，年龄22.5±3.5岁）。平均办公室血压分别为114.5±10.4和73.7±7.5mmHg。40%的学生有非最佳血压（61%为女性），在所有ABPM期间的血压值明显较高，左心室质量指数、心壁厚度、空腹血糖、TyG指数、TG/HDL-c比值较高。7名学生符合夜间高血压诊断标准，其中6人属于非最佳血压组（11.1% vs 1.2%）。结论：因此，我们的研究表明，表面健康的非最佳血压的年轻人，即使不是高血压，与最佳血压的人相比，在一些心血管危险指标上表现出差异。

{"title":"Cardiovascular risk markers in apparently healthy young adults: Evaluation according to optimal or non-optimal office blood pressure.","authors":"W Espeche, O A Pinilla, G Cerri, N Stavile, J Minetto, M R Salazar, I L Ennis","doi":"10.1016/j.hipert.2024.11.006","DOIUrl":"https://doi.org/10.1016/j.hipert.2024.11.006","url":null,"abstract":"<p><strong>Background: </strong>Blood pressure (BP) is linearly related to the incidence of cardiovascular disease from values as low as 115/75mmHg, even at young ages. A particularly concerning issue is the decrease representation of optimal BP among children and youth. The mechanisms by which minimal elevations in BP increase cardiovascular risk are not defined. The limitations of office BP measurements could be a possible explanation since 24-h ambulatory measurements (ABPM) better detect the risk of future cardiovascular events. Therefore, we aimed to compare healthy normotensive undergraduate students with optimal vs. non-optimal BP: ABPM, the cardiometabolic risk profile, and echocardiographic characteristics.</p><p><strong>Methods: </strong>Medical students from La Plata voluntarily completed a survey to collect personal and family data on cardiovascular risk factors. Subsequently, anthropometric, BP (office and ABPM), and echocardiography determinations were recorded. Cholesterol, triglycerides, and glucose were measured in fasting blood samples. Statistical analyses were performed blinded, using SPSS software.</p><p><strong>Results: </strong>Data from 135 students were analyzed (76% female, age 22.5±3.5 years). Mean office BP was 114.5±10.4 and 73.7±7.5mmHg. Forty percent of students had non-optimal BP (61% females) showing significantly higher BP values in all ABPM periods and higher left ventricular mass index, cardiac wall thicknesses, fasting glucose, TyG index, TG/HDL-c ratio. Seven students met diagnostic criteria for nocturnal hypertension, six of whom were in the non-optimal BP group (11.1% vs 1.2%).</p><p><strong>Conclusions: </strong>Therefore, our study shows that apparently healthy young individuals with non-optimal BP, even if not hypertensive, exhibit differences in several cardiovascular risk markers compared to those with optimal BP.</p>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142910900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Position statement on the use of amlodipine during pregnancy. Working Group on Hypertension in Women, Argentine Society of Hypertension]. [妊娠期间使用氨氯地平的立场声明。]阿根廷高血压学会妇女高血压工作组]。

IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Hipertension y Riesgo Vascular

Pub Date : 2024-12-24 DOI: 10.1016/j.hipert.2024.11.004

Albertina M Ghelfi, Gonzalo Miranda, Liliana S Voto, Mildren A Del Sueldo, Judith M Zilberman, Roxana Mondino, Mariana P Pérez, Pablo G Irusta, Laura Meccia, Evangelina Martínez Marissi, María Laura Baiche, Florencia Waisman, Marcos BaronI, María Victoria FerrettI, Joana P Morán, Andrea Corrales Barboza, Alejandro M Delucchi, Pablo D Rodríguez, Nicolás F Renna

Pharmacological management of HDP includes agents supported by extensive evidence ensuring their safety for use. Among those traditionally described in the literature are: alpha-methyldopa, labetalol, and sustained-release nifedipine (NIF-RETARD). These drugs, in addition to being compatible with pregnancy, present additional eligibility criteria. The discontinuation of NIF-RETARD has resulted in the off-label use of other dihydropyridine calcium cannel blockers with lower levels of evidence in pregnancy, such as amlodipine. The Working Group Hypertension in Women of the Argentine Society of Hypertension has proposed to develop a document that precisely and thoroughly addresses the concerns related to the use of amlodipine in pregnancy, providing responses based on the currently available scientific evidence.

HDP的药理学管理包括有大量证据支持的药物，以确保其使用安全。传统文献中描述的有：甲多巴、拉贝他洛尔和缓释硝苯地平（NIF-RETARD）。这些药物除了与妊娠相容外，还提出了额外的资格标准。NIF-RETARD的停药导致了其他双氢吡啶钙通道阻滞剂的超说明书使用，如氨氯地平，证据表明其在妊娠期的使用水平较低。阿根廷高血压学会妇女高血压工作组建议制定一份文件，精确和彻底地解决与妊娠期间使用氨氯地平有关的问题，根据现有的科学证据提供答复。

{"title":"[Position statement on the use of amlodipine during pregnancy. Working Group on Hypertension in Women, Argentine Society of Hypertension].","authors":"Albertina M Ghelfi, Gonzalo Miranda, Liliana S Voto, Mildren A Del Sueldo, Judith M Zilberman, Roxana Mondino, Mariana P Pérez, Pablo G Irusta, Laura Meccia, Evangelina Martínez Marissi, María Laura Baiche, Florencia Waisman, Marcos BaronI, María Victoria FerrettI, Joana P Morán, Andrea Corrales Barboza, Alejandro M Delucchi, Pablo D Rodríguez, Nicolás F Renna","doi":"10.1016/j.hipert.2024.11.004","DOIUrl":"https://doi.org/10.1016/j.hipert.2024.11.004","url":null,"abstract":"<p><p>Pharmacological management of HDP includes agents supported by extensive evidence ensuring their safety for use. Among those traditionally described in the literature are: alpha-methyldopa, labetalol, and sustained-release nifedipine (NIF-RETARD). These drugs, in addition to being compatible with pregnancy, present additional eligibility criteria. The discontinuation of NIF-RETARD has resulted in the off-label use of other dihydropyridine calcium cannel blockers with lower levels of evidence in pregnancy, such as amlodipine. The Working Group Hypertension in Women of the Argentine Society of Hypertension has proposed to develop a document that precisely and thoroughly addresses the concerns related to the use of amlodipine in pregnancy, providing responses based on the currently available scientific evidence.</p>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence of antihypertensive medication adherence and associated factors in India: A systematic review and meta-analysis. 印度抗高血压药物依从性患病率及相关因素：系统回顾和荟萃分析

IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Hipertension y Riesgo Vascular

Pub Date : 2024-12-21 DOI: 10.1016/j.hipert.2024.11.005

B Pal, A Dutta, V Chaudhary, S Kumari, S Meenakshi, K Murti

Background: Non-adherence to antihypertensive medication is a key factor contributing to uncontrolled blood pressure and the subsequent complications of hypertension. Despite its importance, there is a lack of data regarding the prevalence of and factors associated with non-adherence to medication among individuals with hypertension in India. This review aimed to assess medication adherence rates among hypertensive patients in India and identify the factors influencing non-adherence.

Methods: A comprehensive search was conducted across PubMed, Scopus, Embase, and Google Scholar. Studies reporting medication adherence/non-adherence to antihypertensive medications in India, using the Morisky Medication Adherence Scale (MMAS), with publication dates up to July 2023, were included.

Results: Twelve studies were included, involving a total of 3164 participants. The pooled rate of medication adherence to antihypertensive medications in India was determined to be 15.8% (95% CI: 4.4; 43.4). The important factors associated with non-adherence included higher age, medication regimen complexity, low socioeconomic status, low education levels, uncontrolled blood pressure, and comorbidities.

Conclusions: The adherence rate to antihypertensive medication was observed to be quite low. Therefore, it is imperative to enhance the rate of medication adherence among individuals with hypertension in order to attain effective blood pressure control and reduce the burden of non-communicable diseases.

背景：不坚持降压药物治疗是导致血压失控和高血压并发症的关键因素。尽管它很重要，但缺乏关于印度高血压患者不坚持服药的患病率和相关因素的数据。本综述旨在评估印度高血压患者的药物依从率，并确定影响不依从性的因素。方法：在PubMed、Scopus、Embase和谷歌Scholar中进行综合检索。纳入了使用Morisky药物依从性量表（MMAS）报告印度降压药依从性/不依从性的研究，出版日期截止到2023年7月。结果：纳入12项研究，共涉及3164名受试者。印度抗高血压药物的总依从率为15.8% (95% CI: 4.4；43.4)。与不依从性相关的重要因素包括年龄较大、用药方案复杂、低社会经济地位、低教育水平、未控制的血压和合并症。结论：降压药物依从率较低。因此，提高高血压患者的服药依从率，以实现有效的血压控制，减轻非传染性疾病的负担，势在必行。

{"title":"Prevalence of antihypertensive medication adherence and associated factors in India: A systematic review and meta-analysis.","authors":"B Pal, A Dutta, V Chaudhary, S Kumari, S Meenakshi, K Murti","doi":"10.1016/j.hipert.2024.11.005","DOIUrl":"https://doi.org/10.1016/j.hipert.2024.11.005","url":null,"abstract":"<p><strong>Background: </strong>Non-adherence to antihypertensive medication is a key factor contributing to uncontrolled blood pressure and the subsequent complications of hypertension. Despite its importance, there is a lack of data regarding the prevalence of and factors associated with non-adherence to medication among individuals with hypertension in India. This review aimed to assess medication adherence rates among hypertensive patients in India and identify the factors influencing non-adherence.</p><p><strong>Methods: </strong>A comprehensive search was conducted across PubMed, Scopus, Embase, and Google Scholar. Studies reporting medication adherence/non-adherence to antihypertensive medications in India, using the Morisky Medication Adherence Scale (MMAS), with publication dates up to July 2023, were included.</p><p><strong>Results: </strong>Twelve studies were included, involving a total of 3164 participants. The pooled rate of medication adherence to antihypertensive medications in India was determined to be 15.8% (95% CI: 4.4; 43.4). The important factors associated with non-adherence included higher age, medication regimen complexity, low socioeconomic status, low education levels, uncontrolled blood pressure, and comorbidities.</p><p><strong>Conclusions: </strong>The adherence rate to antihypertensive medication was observed to be quite low. Therefore, it is imperative to enhance the rate of medication adherence among individuals with hypertension in order to attain effective blood pressure control and reduce the burden of non-communicable diseases.</p>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of the effectiveness of aliskiren and ramipril for the management of hypertension: A systematic review and meta-analysis. 阿利克伦和雷米普利治疗高血压的疗效比较：一项系统回顾和荟萃分析。

IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Hipertension y Riesgo Vascular

Pub Date : 2024-12-10 DOI: 10.1016/j.hipert.2024.11.002

T Alam, M Asif Ansari

Objective: Ramipril is an important option in the management of hypertension, while the role of aliskiren is still up for debate. We aim to meta-analyse and compare the effect of aliskiren with ramipril by measuring mean difference in systolic blood pressure (mdSBP) and mean difference in diastolic blood pressure (mdDBP).

Methods: The search was conducted using the PubMed and Cochrane databases for eligible randomized clinical trials (RCTs) to perform a meta-analysis from January 2000 to May 2024. RCTs that included hypertensive patients who were under either aliskiren or ramipril treatment were included in the analysis. The risk of bias was evaluated using RoB 2.0. This study is registered with PROSPERO: CRD42024577105.

Results: Four studies were included: two studies were carried out for 2 months, and two were carried out for 6 months, including 693 and 329 patients, respectively, with mild to moderate hypertension and a mean age of 55.2 years. After 2 months, mdDBP was found to be significant (mdDBP=0.85mmHg, 95% CI: 0.73-0.97, I²=0%), but mdSBP was found to be non-significant (mdSBP=0.0mmHg, 95% CI: -0.17-0.17, I²=0%). There was a significant difference in the mdSBP (mdSBP=3.15mmHg, 95% CI: 2.13-4.17, I²=84%) and mdDBP (mdDBP=1.2mmHg, 95% CI: 1.09-1.31, I²=0%) at 6 months.

Conclusion: Aliskiren provides, in the short term, a slight improvement in BP in non-elderly hypertensive patients without diabetes or previous cardio-cerebrovascular disease.

目的：雷米普利是治疗高血压的重要选择，而阿利克伦的作用仍存在争议。我们的目的是通过测量收缩压（mdSBP）和舒张压（mdDBP）的平均差值，对阿利克伦和雷米普利的疗效进行荟萃分析和比较。方法：使用PubMed和Cochrane数据库检索2000年1月至2024年5月的符合条件的随机临床试验（rct）进行meta分析。纳入阿利克伦或雷米普利治疗的高血压患者的随机对照试验被纳入分析。偏倚风险采用rob2.0进行评估。本研究已注册为PROSPERO: CRD42024577105。结果：纳入4项研究，2项研究2个月，2项研究6个月，分别纳入693例和329例患者，轻至中度高血压，平均年龄55.2岁。2个月后，mdDBP显著（mdDBP=0.85mmHg, 95% CI: 0.73-0.97, I2=0%）， mdSBP无显著性（mdSBP=0.0mmHg, 95% CI: -0.17-0.17, I2=0%）。6个月时mdSBP （mdSBP=3.15mmHg, 95% CI: 2.13-4.17, I2=84%）和mdDBP （mdDBP=1.2mmHg, 95% CI: 1.09-1.31, I2=0%）差异有统计学意义。结论：Aliskiren可在短期内轻微改善无糖尿病或既往心脑血管疾病的非老年高血压患者的血压。

{"title":"Comparison of the effectiveness of aliskiren and ramipril for the management of hypertension: A systematic review and meta-analysis.","authors":"T Alam, M Asif Ansari","doi":"10.1016/j.hipert.2024.11.002","DOIUrl":"https://doi.org/10.1016/j.hipert.2024.11.002","url":null,"abstract":"<p><strong>Objective: </strong>Ramipril is an important option in the management of hypertension, while the role of aliskiren is still up for debate. We aim to meta-analyse and compare the effect of aliskiren with ramipril by measuring mean difference in systolic blood pressure (mdSBP) and mean difference in diastolic blood pressure (mdDBP).</p><p><strong>Methods: </strong>The search was conducted using the PubMed and Cochrane databases for eligible randomized clinical trials (RCTs) to perform a meta-analysis from January 2000 to May 2024. RCTs that included hypertensive patients who were under either aliskiren or ramipril treatment were included in the analysis. The risk of bias was evaluated using RoB 2.0. This study is registered with PROSPERO: CRD42024577105.</p><p><strong>Results: </strong>Four studies were included: two studies were carried out for 2 months, and two were carried out for 6 months, including 693 and 329 patients, respectively, with mild to moderate hypertension and a mean age of 55.2 years. After 2 months, mdDBP was found to be significant (mdDBP=0.85mmHg, 95% CI: 0.73-0.97, I<sup>2</sup>=0%), but mdSBP was found to be non-significant (mdSBP=0.0mmHg, 95% CI: -0.17-0.17, I<sup>2</sup>=0%). There was a significant difference in the mdSBP (mdSBP=3.15mmHg, 95% CI: 2.13-4.17, I<sup>2</sup>=84%) and mdDBP (mdDBP=1.2mmHg, 95% CI: 1.09-1.31, I<sup>2</sup>=0%) at 6 months.</p><p><strong>Conclusion: </strong>Aliskiren provides, in the short term, a slight improvement in BP in non-elderly hypertensive patients without diabetes or previous cardio-cerebrovascular disease.</p>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Physicians' perception of guideline recommendations for the treatment of resistant hypertension by renal denervation: Resistant Hypertension Working Group, Argentine Hypertension Society. 医生对肾去神经支配治疗顽固性高血压的指南建议的看法：阿根廷高血压学会顽固性高血压工作组。

IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Hipertension y Riesgo Vascular

Pub Date : 2024-12-06 DOI: 10.1016/j.hipert.2024.10.003

N F Renna, L Brandani, R Parodi, C Kottliar, E Ylarri, G Lavenia, M Marin, M Ruise, R Sanchez, D Cianfagna, G Botvinik, P Rumi, V Ferreti, P Rodirguez

Introduction: This study investigates the perceptions and knowledge of specialized Argentine physicians regarding renal denervation (RDN) as a treatment for resistant hypertension (R-HT).

Method: A survey was conducted among 206 physicians, mainly cardiologists and internists, to assess their awareness and perceptions of RDN. Data were analyzed using descriptive statistics and Spearman's Rho correlation.

Results: The survey revealed that 83% of the responders are aware of RDN. Despite this high awareness, only 60% believe in its safety, while 33.2% are uncertain, and 6.8% consider it unsafe. Significant correlations were found between the awareness of RDN and perceptions of its efficacy and safety.

Conclusions: The study highlights a gap between knowledge and confidence in RDN among specialized Argentine physicians. Continuous education and shared decision-making are crucial to improve the adoption of RDN in clinical practice. Long-term safety and efficacy data support RDN as a valuable tool for managing R-HT. Addressing safety concerns through targeted educational initiatives is essential.

简介：本研究调查了阿根廷专业医生对肾去神经支配（RDN）作为顽固性高血压（R-HT）治疗的认知和知识。方法：对206名内科医生（主要是心脏科医生和内科医生）进行调查，了解他们对RDN的认识和看法。数据分析采用描述性统计和Spearman’s Rho相关。结果：调查显示83%的应答者知道RDN。尽管有很高的认知度，但只有60%的人相信它的安全性，33.2%的人不确定，6.8%的人认为它不安全。对RDN的认知与对其有效性和安全性的认知之间存在显著的相关性。结论：该研究突出了阿根廷专业医生对RDN的知识和信心之间的差距。持续教育和共同决策对于提高临床实践中RDN的采用至关重要。长期安全性和有效性数据支持RDN作为治疗R-HT的宝贵工具。通过有针对性的教育举措解决安全问题至关重要。

{"title":"Physicians' perception of guideline recommendations for the treatment of resistant hypertension by renal denervation: Resistant Hypertension Working Group, Argentine Hypertension Society.","authors":"N F Renna, L Brandani, R Parodi, C Kottliar, E Ylarri, G Lavenia, M Marin, M Ruise, R Sanchez, D Cianfagna, G Botvinik, P Rumi, V Ferreti, P Rodirguez","doi":"10.1016/j.hipert.2024.10.003","DOIUrl":"https://doi.org/10.1016/j.hipert.2024.10.003","url":null,"abstract":"<p><strong>Introduction: </strong>This study investigates the perceptions and knowledge of specialized Argentine physicians regarding renal denervation (RDN) as a treatment for resistant hypertension (R-HT).</p><p><strong>Method: </strong>A survey was conducted among 206 physicians, mainly cardiologists and internists, to assess their awareness and perceptions of RDN. Data were analyzed using descriptive statistics and Spearman's Rho correlation.</p><p><strong>Results: </strong>The survey revealed that 83% of the responders are aware of RDN. Despite this high awareness, only 60% believe in its safety, while 33.2% are uncertain, and 6.8% consider it unsafe. Significant correlations were found between the awareness of RDN and perceptions of its efficacy and safety.</p><p><strong>Conclusions: </strong>The study highlights a gap between knowledge and confidence in RDN among specialized Argentine physicians. Continuous education and shared decision-making are crucial to improve the adoption of RDN in clinical practice. Long-term safety and efficacy data support RDN as a valuable tool for managing R-HT. Addressing safety concerns through targeted educational initiatives is essential.</p>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0